The most telling number in Intuitive Surgical’s recent communications isn’t a price target or a revenue projection — it’s 100 percent. That’s the customer retention rate for the first wave of My Intuitive+ contract renewals, processed in the second quarter. Not a single hospital walked away from the software layer that wraps around the da Vinci 5 platform, which delivers data analytics, connectivity, and digital services to complement the robotic hardware.
That quiet metric carries more weight than it might appear. Hospitals that have already committed millions to the physical robots are choosing to keep paying for the digital ecosystem attached to them. It’s the structural bet underpinning the entire investment thesis: the moat isn’t just the machines anymore, it’s the software that connects, monitors, and extracts value from them.
A Tale of Two Timelines
The company is effectively playing on two horizons simultaneously. In the near term, the market is fixated on procedure growth — the metric that triggered a July guidance cut for da Vinci procedures from 18 percent growth to a range of 13.5 to 15.5 percent. That revision sent the stock into a volatile stretch and opened a debate about whether the slowdown is temporary or structural.
On the longer timeline, management is building for the next decade. The lease for a 316,000-square-foot manufacturing facility in Penang, Malaysia, was signed just over a week ago. Production of da Vinci instruments and electromechanical components is slated to begin in 2028, with 1,200 jobs expected by 2032. It’s the company’s first Southeast Asian plant and only its second in Asia after Shanghai, backed by roughly $500 million in investment spread over five years.
The Malaysian expansion isn’t just about growth markets — it’s also a hedge against tariff uncertainty. The company flagged a roughly one percent impact on gross margins from tariffs for 2026, though it did book a $36 million refund from an IEEPA tariff proceeding in the same quarter. Supply-chain diversification has become a strategic imperative for med-tech firms navigating trade policy volatility.
The Analyst Divide Widens
Wall Street remains split on the stock, and Friday’s flurry of ratings actions captured the divergence neatly. Oppenheimer upgraded from “perform” to “outperform” with a $500 price target, citing a re-evaluated risk-reward profile. UBS initiated coverage with a “buy” rating and a $500 target, pointing to the company’s leadership position in medical technology. Piper Sandler reaffirmed its “overweight” stance but trimmed its target from $580 to $470, calling the recent sell-off “unwarranted.”
Should investors sell immediately? Or is it worth buying Intuitive Surgical?
The bearish camp pushed back. HSBC downgraded to “hold” and cut its target. Bernstein SocGen Group reduced its price objective from $750 to $685 on U.S. growth concerns while maintaining “outperform.” The target range — from $470 to $685 among the optimists — underscores how much uncertainty surrounds the pace of procedure growth, the very metric that’s been at the center of the debate since the guidance cut.
The stock has recovered somewhat from the volatility, gaining roughly 3.85 percent after the initial turbulence. In German trading Friday, shares closed at €324.65, up 1.3 percent on the day. Over the past 30 days, the stock is still up 9.6 percent, though it remains 34 percent below its level at the start of the year and sits 4.1 percent below its 50-day average of €338.61. From the January 52-week high, the shares are down about 37 percent, though they’re 12 percent above July’s low.
Clinical Momentum and Insider Caution
Operationally, the company continues to rack up wins. The Kossuth Regional Health Center added a da Vinci 5 system to its surgical suite, and Adventist Health Portland expanded to a third da Vinci 5 device, giving it the largest installation of that platform in the region. These installations suggest demand for the robotic platform remains intact despite the near-term growth hiccup.
Yet a dissonance persists. While the company expands and celebrates customer loyalty, executives keep selling. CEO Gary S. Guthart disposed of 10,000 shares for roughly $4 million in mid-August. EVP Mark Brosius sold 154 shares at prices between $375.57 and $396.37, and director Amy L. Ladd offloaded 472 shares at $379.00 and $393.10. All transactions ran through pre-arranged 10b5-1 trading plans, and over the past six months, data shows 38 insider sales against zero purchases. That’s not necessarily a red flag given the automated nature of these plans, but it doesn’t exactly align with a narrative of unbridled optimism.
Institutional activity tells a similarly mixed story. Plato Investment Management built a new position of roughly 10,914 shares worth about $4.315 million, while Invesco and JPMorgan Chase substantially increased their holdings in the second quarter. Winslow Capital Management, by contrast, shed nearly its entire stake.
The next earnings report lands on October 20. Until then, the stock is likely to oscillate between the competing analyst camps and the unresolved question of whether procedure growth stabilizes. The recent pullback looks less like a crisis than a repricing — investors adjusting expectations for growth velocity while the company quietly positions itself for the long haul, with new factories on one side and deepening software dependence on the other. Whether that dual bet pays off won’t be answered in the coming weeks, but in the coming years.
Ad
Intuitive Surgical Stock: Buy or Sell?! New Intuitive Surgical Analysis from August 24 delivers the answer:
The latest Intuitive Surgical figures speak for themselves: Urgent action needed for Intuitive Surgical investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 24.
Intuitive Surgical: Buy or sell? Read more here...
